Delivery Order SPE2DB22D2009-SPE2DB25FL8RT

Award Date 4/4/25
Potential Completion Date 4/7/25
Potential Value $1.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Methotrexate 2.5 mg tablets to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,653.72, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,475.11, is a delivery order for the supply of 4567221522 METHOTREXATE 2.5 MG TABLET UD 20S. The contract has a period of performance through February 11, 2025 and utilizes a firm fixed price pricing type. This award is part of a larger Indefinite Delivery Contract (IDC) held by...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of METHOTREXATE 2.5 MG TABLET 100S, a prescription medication, with a ceiling value of $2,542.92 and a performance period ending on June 27, 2025. The contract is a firm fixed-price delivery order and is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,820.90, is for the delivery of 4560843534 - METHOTREXATE 2.5 MG TABLET 100S. It is a firm fixed price, delivery order contract with a completion date of May 8, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $1,563.22, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The contract is for the delivery of 4,565,634,382 units of Methotrexate 2.5 mg tablets. The contract has a completion date of August 30, 2024 and is a Firm Fixed Price Delivery Order. This contract is not designated as a set-aside. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple Indefinite Delivery Contracts (IDCs) by the DLA and...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of 4,567,678,591 units of Methotrexate 2.5 mg tablets in 100-count bottles. The contract has a ceiling value of $21,076.61 and runs through March 25, 2025. The contract is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that holds a $999,999,999 Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,076.18 firm fixed-price delivery order is for the supply of 4,566,438,147 units of Methotrexate 2.5 mg tablets, a common medication used to treat various medical conditions. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of METHOTREXATE 2.5 MG TABLET UD 20S, a pharmaceutical product, with a ceiling value of $14,326.92 and a performance period ending on May 19, 2025. The contract is a firm-fixed-price delivery order, and it is not designated as a set-aside contract. Amerisourcebergen Drug...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Methotrexate 2.5 mg tablets. The contract, valued at $2,294.28, is a firm-fixed-price delivery order with a completion date of July 18, 2024. While there is no set-aside designation, AmerisourceBergen has been awarded numerous federal contracts by the DLA and other agencies, including a $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award, with ID SPE2DB22D2009|SPE2DB25FL8VR, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania. The contract is for the delivery of Methotrexate 2.5 mg tablets, a medication used to treat various conditions, and has a ceiling value of $3,779.10. The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 17, 2025. Amerisourcebergen Drug...
  • SPE2DB22D2009
    Indefinite Delivery Contract
  • SPE2DB22D2009-SPE2DB25FL8RT
    Delivery Order

This federal contract award from the Defense Logistics Agency (DLA) is for the delivery of METHOTREXATE 2.5 MG TABLET UD 20S, a pharmaceutical product, to support military healthcare programs. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for a ceiling value of $1,493.54. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 7/4/25, 11:14 AM